Axovant Sciences Ltd (NYSE:AXON) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

AXON has been the subject of several other research reports. Jefferies Group LLC set a $40.00 price objective on Axovant Sciences and gave the company a “buy” rating in a research note on Friday, August 25th. Evercore ISI started coverage on Axovant Sciences in a research note on Friday, September 8th. They set an “outperform” rating and a $30.00 price objective for the company. CIBC lifted their price objective on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Oppenheimer Holdings, Inc. lifted their price objective on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Finally, Chardan Capital reissued a “sell” rating and set a $8.00 price objective on shares of Axovant Sciences in a research note on Thursday. Four analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $26.05.

Shares of Axovant Sciences (NYSE:AXON) traded up 9.32% during trading on Friday, reaching $21.34. The company’s stock had a trading volume of 1,190,621 shares. Axovant Sciences has a 52-week low of $11.01 and a 52-week high of $21.85. The stock’s market cap is $2.29 billion. The stock has a 50-day moving average of $20.44 and a 200-day moving average of $17.12.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.12). Analysts predict that Axovant Sciences will post ($2.36) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Axovant Sciences Ltd (AXON) Downgraded by BidaskClub” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/16/axovant-sciences-ltd-axon-downgraded-by-bidaskclub.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its position in Axovant Sciences by 1.6% during the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock valued at $528,000 after purchasing an additional 355 shares in the last quarter. American International Group Inc. raised its position in Axovant Sciences by 7.1% during the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 998 shares in the last quarter. Legal & General Group Plc raised its position in Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 1,168 shares in the last quarter. Teachers Advisors LLC raised its position in Axovant Sciences by 5.2% during the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 2,038 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Axovant Sciences by 38.9% during the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 2,072 shares in the last quarter.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.